A medicine developed to treat age-related macular degeneration (AMD) may also help patients with diabetic macular edema (DME), a new nationwide, government-funded study finds.

Low levels of high-density lipoprotein (HDL or "good" cholesterol) and smoking appear to contribute to early-stage age-related macular degeneration (AMD), according to a recent study.

Researchers at Boston University School of Medicine found little difference in the efficacy of the treatments Bevacizumab (Avastin) and Ranibizumab (Lucentis), used to treat age-related macular degeneration (AMD).